<?xml version="1.0" encoding="utf-8" ?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Cision Wire</title>
    <link>http://news.cision.com/</link>
    <description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description>
    <pubDate>Tue, 21 May 2013 18:48:48 GMT</pubDate>
    <image>
      <title>Cision Wire</title>
      <width>120</width>
      <height>32</height>
      <link>http://news.cision.com/</link>
      <url>http://news.cision.com/ui/images/CisionLogoSmall.gif</url>
    </image>
    <item>
      <title>Galderma and NovaBay Enroll First Patients in Phase 2b Clinical Study of NVC-422 for Impetigo</title>
      <link>http://news.cision.com/novabay-pharmaceuticals-g/r/galderma-and-novabay-enroll-first-patients-in-phase-2b-clinical-study-of-nvc-422-for-impetigo,e332452</link>
      <guid isPermaLink="false">cision1124108</guid>
      <description><![CDATA[]]></description>
      <pubDate>Wed, 26 Sep 2012 04:02:17 GMT</pubDate>
    </item>
  </channel>
</rss>